JP2016538878A - 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法 - Google Patents

糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法 Download PDF

Info

Publication number
JP2016538878A
JP2016538878A JP2016547823A JP2016547823A JP2016538878A JP 2016538878 A JP2016538878 A JP 2016538878A JP 2016547823 A JP2016547823 A JP 2016547823A JP 2016547823 A JP2016547823 A JP 2016547823A JP 2016538878 A JP2016538878 A JP 2016538878A
Authority
JP
Japan
Prior art keywords
group
antibody
hetero
udp
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016547823A
Other languages
English (en)
Japanese (ja)
Inventor
デルフト， フローリス ルイ ファン
デルフト， フローリス ルイ ファン
ヘール， レモン ファン
ヘール， レモン ファン
マリア アントニア ウェイデーヴェン，
マリア アントニア ウェイデーヴェン，
Original Assignee
シンアフィックス ビー．ブイ．
シンアフィックス ビー．ブイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンアフィックス ビー．ブイ．, シンアフィックス ビー．ブイ． filed Critical シンアフィックス ビー．ブイ．
Publication of JP2016538878A publication Critical patent/JP2016538878A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2016547823A 2013-10-14 2014-10-14 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法 Pending JP2016538878A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13188585.7 2013-10-14
EP13188585 2013-10-14
EP14165581 2014-04-23
EP14165581.1 2014-04-23
PCT/NL2014/050717 WO2015057066A1 (en) 2013-10-14 2014-10-14 Glycoengineered antibody, antibody-conjugate and methods for their preparation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020035173A Division JP7041182B2 (ja) 2013-10-14 2020-03-02 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法

Publications (1)

Publication Number Publication Date
JP2016538878A true JP2016538878A (ja) 2016-12-15

Family

ID=51842732

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016547823A Pending JP2016538878A (ja) 2013-10-14 2014-10-14 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法
JP2020035173A Expired - Fee Related JP7041182B2 (ja) 2013-10-14 2020-03-02 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020035173A Expired - Fee Related JP7041182B2 (ja) 2013-10-14 2020-03-02 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法

Country Status (5)

Country Link
US (1) US20160257764A1 (enExample)
EP (2) EP3929301A1 (enExample)
JP (2) JP2016538878A (enExample)
CN (1) CN105829543B (enExample)
WO (1) WO2015057066A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019206491A (ja) * 2018-05-29 2019-12-05 国立研究開発法人理化学研究所 乳がんまたは胃がんの治療のための抗体−薬物複合体

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
US20160235861A1 (en) * 2013-10-14 2016-08-18 SynAffix. B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
US10905678B2 (en) 2014-04-08 2021-02-02 University Of Georgia Research Foundation, Inc. Site-specific antibody-drug glycoconjugates and methods
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
EP3402815B1 (en) * 2016-01-15 2023-12-06 University of Maryland, College Park Endo-s2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins
RU2018128784A (ru) * 2016-01-27 2020-02-27 МЕДИММЬЮН, ЭлЭлСи Способы получения антител с заданным профилем гликозилирования
WO2017137458A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
JP2017197512A (ja) * 2016-02-08 2017-11-02 シンアフィックス ビー．ブイ． Ｃｄ３０腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
WO2017137456A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
JP2017200902A (ja) * 2016-02-08 2017-11-09 シンアフィックス ビー．ブイ． Ｈｅｒ２腫瘍を標的化するための改善された治療指数を有する新規な抗体−コンジュゲート及び抗体−コンジュゲートの治療指数を改善するための方法
US11590239B2 (en) 2016-02-08 2023-02-28 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137457A1 (en) * 2016-02-08 2017-08-17 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting cd30 tumours and method for improving therapeutic index of antibody-conjugates
US10874746B2 (en) 2016-02-08 2020-12-29 Synaffix B.V. Sulfamide linkers for use in bioconjugates
EP3474901B1 (en) 2016-06-27 2025-08-06 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
CN109715819A (zh) 2016-08-10 2019-05-03 马里兰大学帕克分校 设计者α1,6-岩藻糖苷酶突变体实现完整N-糖肽和N-糖蛋白的直接核心岩藻糖基化
US11135306B2 (en) * 2016-11-14 2021-10-05 CHO Pharma Inc. Antibody-drug conjugates
US11459380B2 (en) 2017-06-29 2022-10-04 University Of Maryland, College Park Transglycosylation of endo-S and endo-S mutants for antibody glycosylation remodeling
CN107501388A (zh) * 2017-09-22 2017-12-22 上海美吉医学检验有限公司 一种用于抗体‑分子定点偶联的方法及应用
MX2020003125A (es) 2017-09-29 2020-10-01 Daiichi Sankyo Co Ltd Conjugado de anticuerpo-derivado de pirrolobenzodiazepina.
CA3082231A1 (en) 2017-11-09 2019-05-16 National Research Council Of Canada Antibody glycoconjugates and methods of production and use
BR112020012099A2 (pt) 2017-12-18 2020-11-17 Janssen Biotech, Inc. radiomarcação de polipeptídeos
PT3848054T (pt) 2018-09-06 2025-04-03 Daiichi Sankyo Co Ltd Conjugados anticorpo-fármaco de derivados de dinucleótidos cíclicos
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
EP3986939A4 (en) * 2019-06-24 2023-07-26 University of Georgia Research Foundation, Inc. DUAL DRUG-ANTIBODY-DUG CONJUGATES
NL2023572B1 (en) * 2019-07-25 2021-02-10 Synaffix Bv Synthesis of 6-azido-6-deoxy-2-N-acetyl-hexosamine-nucleoside diphosphate
US20220193251A1 (en) 2020-12-23 2022-06-23 Ludwig-Maximilians-Universitaet Muenchen Cd30 targeting antibody drug conjugates and uses thereof
WO2022136705A1 (en) * 2020-12-24 2022-06-30 Synaffix B.V. Glycan-conjugated antibodies binding to fc-gamma receptor
EP4301782A1 (en) 2021-03-05 2024-01-10 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
CA3215049A1 (en) 2021-04-10 2022-10-13 Baiteng ZHAO Folr1 binding agents, conjugates thereof and methods of using the same
AU2022262644A1 (en) 2021-04-23 2023-11-09 Genmab A/S Anti-cd70 antibodies, conjugates thereof and methods of using the same
EP4380604A1 (en) 2021-08-05 2024-06-12 Go Therapeutics, Inc. Anti-glyco-muc4 antibodies and their uses
EP4433096A1 (en) 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
EP4615513A1 (en) * 2022-11-07 2025-09-17 Merck Sharp & Dohme LLC Bisecting-glycan bridged conjugation for producing glycoprotein conjugates
WO2024153232A1 (zh) * 2023-01-19 2024-07-25 上海盛迪医药有限公司 酪氨酸酶介导的蛋白定点偶联及其应用
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025072406A1 (en) 2023-09-26 2025-04-03 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
US20250381289A1 (en) 2024-02-29 2025-12-18 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
CN120227472A (zh) * 2024-11-12 2025-07-01 云舟生物科技(广州)股份有限公司 脂质纳米颗粒偶联物及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528988A (ja) * 2006-02-10 2009-08-13 ライフ テクノロジーズ コーポレーション 翻訳後修飾されたタンパク質の標識及び検出方法
JP2009531289A (ja) * 2006-02-10 2009-09-03 ライフ テクノロジーズ コーポレーション オリゴ糖によるタンパク質の修飾及び標識方法
JP2010506568A (ja) * 2006-10-12 2010-03-04 ジェネンテック インコーポレイテッド リンホトキシン−αに対する抗体
JP2011121954A (ja) * 2003-01-09 2011-06-23 Macrogenics Inc 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
JP2013534535A (ja) * 2010-07-12 2013-09-05 コヴェックス・テクノロジーズ・アイルランド・リミテッド 多機能性抗体複合体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69729283T2 (de) 1996-03-20 2005-05-25 Immunomedics, Inc. GLYKOSYLIERTE IgG ANTIKÖRPER
JP2006518192A (ja) 2003-01-10 2006-08-10 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ， ナショナル インステ 供与体および受容体の特異性が変化したβ（１，４）−ガラクトシルトランスフェラーゼＩの触媒ドメイン、ｉｎｖｉｔｒｏタンパク質フォールディングを促進するドメイン、およびそれらの使用方法
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CA2647632C (en) 2006-03-27 2017-06-27 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
US8425901B2 (en) 2007-08-22 2013-04-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alpha 1-3 N-galactosyltransferase with altered donor specificities
DK2222341T3 (en) 2007-11-21 2015-03-09 Univ Georgia AND METHODS alkynes of reacting alkynes of 1,3-dipole FUNCTIONAL COMPOUNDS
US8815237B2 (en) * 2007-12-05 2014-08-26 Massachusetts Institute Of Technology Aglycosylated immunoglobulin mutants
WO2009102820A2 (en) 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US8519122B2 (en) 2010-02-12 2013-08-27 The Regents Of The University Of California Compositions and methods for modification of biomolecules
CN103153927B (zh) 2010-04-27 2017-02-15 西纳福克斯股份有限公司 稠合的环辛炔化合物及其在无金属点击反应中的应用
GB201115841D0 (en) 2011-09-13 2011-10-26 Genovis Ab Protein and method
HRP20180268T1 (hr) * 2012-10-23 2018-03-23 Synaffix B.V. Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
US20160235861A1 (en) * 2013-10-14 2016-08-18 SynAffix. B.V. Glycoengineered antibody, antibody-conjugate and methods for their preparation
US11590239B2 (en) * 2016-02-08 2023-02-28 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011121954A (ja) * 2003-01-09 2011-06-23 Macrogenics Inc 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
JP2009528988A (ja) * 2006-02-10 2009-08-13 ライフ テクノロジーズ コーポレーション 翻訳後修飾されたタンパク質の標識及び検出方法
JP2009531289A (ja) * 2006-02-10 2009-09-03 ライフ テクノロジーズ コーポレーション オリゴ糖によるタンパク質の修飾及び標識方法
JP2010506568A (ja) * 2006-10-12 2010-03-04 ジェネンテック インコーポレイテッド リンホトキシン−αに対する抗体
JP2013534535A (ja) * 2010-07-12 2013-09-05 コヴェックス・テクノロジーズ・アイルランド・リミテッド 多機能性抗体複合体

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AGNEW B. ET AL., J. BIOMOL. TECH, vol. Vol. 23, No. Supp.8(2012), JPN6017040248, pages 28 - 115, ISSN: 0003921465 *
ALMEIDA G. ET AL., ANGEW. CHEM. INT. ED., vol. Vol. 51(2012), JPN6018038509, pages 2443 - 2447, ISSN: 0004140087 *
HUANG W. ET AL., J. AM. CHEM. SOC., vol. Vol.134(2012), JPN6018038504, pages 12308 - 12318, ISSN: 0003921464 *
RAMAKRISHNAN B. ET AL., J. BIOL. CHEM., vol. Vol.277, No.23(2002), JPN6018045252, pages 20833 - 20839, ISSN: 0004140086 *
STROP P. ET AL., CHEMISTRY & BIOLOGY, vol. 20(2013 Feb), JPN6018045251, pages 161 - 167, ISSN: 0004140085 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019206491A (ja) * 2018-05-29 2019-12-05 国立研究開発法人理化学研究所 乳がんまたは胃がんの治療のための抗体−薬物複合体

Also Published As

Publication number Publication date
EP2935611B1 (en) 2021-07-07
EP2935611A1 (en) 2015-10-28
CN105829543A (zh) 2016-08-03
CN105829543B (zh) 2021-06-01
WO2015057066A1 (en) 2015-04-23
JP2020114818A (ja) 2020-07-30
JP7041182B2 (ja) 2022-03-23
EP3929301A1 (en) 2021-12-29
US20160257764A1 (en) 2016-09-08

Similar Documents

Publication Publication Date Title
JP7041182B2 (ja) 糖鎖工学的に操作された抗体、抗体コンジュゲート、及びそれらの調製方法
EP3057618B1 (en) Glycoengineered antibody, antibody-conjugate and methods for their preparation
JP7167071B2 (ja) 修飾抗体、抗体コンジュゲート及びそれらを調製する方法
US10072096B2 (en) Modified glycoprotein, protein-conjugate and process for the preparation thereof
EP3058083B1 (en) Modified glycoprotein, protein-conjugate and process for the preparation thereof
WO2022037665A1 (en) Site-specific antibody conjugates and the methods for preparation of the same
CN113260384A (zh) 用于靶向表达trop-2的肿瘤的抗体缀合物
AU2015243512A1 (en) Site-specific antibody-drug glycoconjugates and methods
WO2023141855A1 (en) Protein conjugates with multiple payloads and methods for making the same
WO2023065137A1 (en) Site-specific glycoprotein conjugates and methods for making the same
CN118056009A (zh) 分离的多肽及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171012

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190520

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191029